Cefodizime: pharmacological characteristics and potential for clinical use in lower respiratory tract infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(3):277-282

​ Rachina S.А., Alkhlavov A.A., Gasanova D.R., Golub A.V.
10.36488/cmac.2023.3.277-282
cefodizime cephalosporins community-acquired pneumonia chronic obstructive pulmonary disease lower respiratory tract infections pneumococci antimicrobial resistance
Section
Antimicrobials
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(3):277-282

Abstract

Cefodizime is a third–generation cephalosporin for parenteral use that has become available for the first time in the Russia. This paper reviews the use of this antibiotic in clinical practice based on the current data on antimicrobial resistance in pathogens causing lower respiratory tract infections and the results of completed clinical studies of its efficacy and safety.

Rachina S.А.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Alkhlavov A.A.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Gasanova D.R.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Alexey V. Golub

Smolensk State Medical University, Smolensk, Russia

  • 1. Linzenmeier G., Rosenthal E. In vitro testing of newer cephalosporins. Infection. German. 1979;7(Suppl. 2):S225–7. DOI: 10.1007/BF01641128
  • 2. Zajcev A.A., Vlasova A.V. Compliance with antibacterial therapy of respiratory tract infections. Farmateka. 2016;20:43–48. Russian.
  • 3. Limbert M., Klesel N., Seeger K., Seibert G., Winkler I., Schrinner E. Cefodizime, an aminothiazolylcephalosporin. J Antibiot. 1984;37(8):892–900. DOI: 10.7164/antibiotics.37.892
  • 4. Matsumoto K. Cefodizime: The Japanese clinical experience. Infection. 1992;20(Suppl. 1):S31–5. DOI: 10.1007/BF01709948
  • 5. Bassi O., Zuccarelli S., Amalfitano M. Clinical and economic outcomes of empiric parenteral antibiotic therapy for pneumonia: a retrospective study of 1,032 hospitalized patients. J Chemother. 1998;10(5):369– 374. DOI: 10.1179/joc.1998.10.5.369
  • 6. Ren X., Liu D., Ding N., Huang K., Xiong Y., Du G., et al. Safety evaluation of cephalosporins based on utilization and adverse drug events: analysis of two databases in China. Expert Opin Drug Saf. 2012;11(5):689–697. DOI: 10.1517/14740338.2012.699037
  • 7. Barradel L.B., Brogden R.N. Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1992;44(5):800–834. DOI: 10.2165/00003495–199244050–00008
  • 8. Barré J. Pharmacokinetics of cefodizime: a review of the data on file. J Antimicrob Chemother. 1990;26(Suppl. C):95– 101. DOI: 10.1093/jac/26.suppl_c.95
  • 9. Brockmeier D., Dagrosa E. Pharmacokinetic profile of cefodizime. Infection. 1992;20(Suppl. 1):S14–7. DOI: 10.1007/BF01709944
  • 10. Loffreda A., Lampa E., Lucarelli C., Amorena M., Contaldi C., Calderaro V., et al. Pharmacokinetics of cefodizime in patients with various degrees of renal failure. Chemotherapy. 1999;45(1):1–7. DOI: 10.1159/000007158
  • 11. Meyer B., Traunmueller F., Bojic A., Locker G., Schmid R., Winkler S., et al. Single-dose pharmacokinetics of cefodizime in critically ill elderly patients. Int J Antimicrob Agents. 2006;27(4):335–338. DOI: 10.1016/j.ijantimicag.2005.11.018
  • 12. Drago L., Mombelli B., Fassina M.C., De Vecchi E., Gismondo M.R. Evaluation of antibacterial activity of cefodizime, ceftriaxone and cefonicid in Klebsiella pneumoniae-infected guinea pigs. Clin Microbiol Infect. 1999;5:371–373. DOI: 10.1111/j.1469–0691.1999.tb00156.x
  • 13. Blandino G., Milazzo I., Musumeci R., Nicolosi V.M., Speciale A., Nicoletti G. Comparative activity of cefodizime and ceftriaxone against respiratory pathogens in an in vitro pharmacodynamic model simulating concentrationtime curves. J Chemother. 2000;12(6):503–508. DOI: 10.1179/joc.2000.12.6.503
  • 14. Suzuki Y., Ishihara R., Ishii Y., Nakazawa A., Deguchi K., Matsumoto Y., et al. Antimicrobial activity of cefodizime against clinical isolates. Jpn J Antibiot. Japanese. 1996;49(10):947–965. PMID: 8986558.
  • 15. Jones R.N., Barry A.L., Thornsberry C., Wilson H.W. In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin. Antimicrob Agents Chemother. 1981;20(6):760–768. DOI: 10.1128/AAC.20.6.760
  • 16. Ahonkhai V.I., Cherubin C.E., Shulman M.A. In vitro activity of cefodizime (HR-221). Antimicrob Agents Chemother. 1982;22(4):715–718. DOI: 10.1128/AAC.22.4.715
  • 17. Paniara O., Platsouka E., Dimopoulou H., Constantoulaki S. In vitro evaluation of cefodizime, cefuroxime, ceftriaxone against respiratory pathogens. J Chemother. 1994;6(1):35– 38. DOI: 10.1080/1120009x.1994.11741126
  • 18. Nicoletti G., Blandino G., Cocuzza G., Dainelli B., Maida A., Debbia E., et al. Comparative in vitro activity of cefodizime and other antibiotics against pathogens recently isolated in Italy. Chemotherapy. 1996;42(2):100– 106. DOI: 10.1159/000239428
  • 19. Kuzmenkov A.Ju., Trushin I.V., Avramenko A.A., Edelstein M.V., Dekhnich A.V., Kozlov R.S. AMRmap: an online platform for monitoring antibiotic resistance. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2017;19(2):84–90. Russian.
  • 20. Vanholder R., Van Landschoot N., Dagrosa E., Ringoir S. Cefodizime: a new cephalosporin with apparent immunestimulating properties in chronic renal failure. Nephrol Dial Transplant. 1988;3(2):221–224. PMID: 3140091.
  • 21. Bergeron Y., Ouellet N., Deslauriers A-M., Simard M., Olivier M., Bergeron M.G. Reduction by cefodizime of the pulmonary inflammatory response induced by heat-killed Streptococcus pneumoniae in mice. Antimicrob Agents Chemother. 1998;42(10)2527–2533. DOI: 10.1128/AAC.42.10.2527
  • 22. Song H., Li G., Ye J., Wan F., Qian Y. Immunomodulating effects of cefodizime on Klebsiella pneumoniae-stimulated neutrophils. Immunobiology. 2004;209(3):277–282. DOI: 10.1016/j.imbio.2004.05.003
  • 23. Wang B., Bian R., Wei C., Sun S., Gao P. Cefodizime increases peripheral blood CD4/CD8 and Th1/Th2 ratios in senile patients with bacterial pneumonia. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015;31(4):528–531. PMID: 25854575.
  • 24. Grassi G.G. Cefodizime in clinical use: a review of the clinical trial reports. J Antimicrob Chemother. 1990;26(Suppl. C):117–125. DOI: 10.1093/jac/26.suppl_c.117
  • 25. Maesen F.P.V., Davies B.I., van den Bergh J.J.A.M., Gubbelmansd H.L.L., Meek J.C.E., Geraedts W.H. Cefodizime and cefotaxime in acute exacerbations of chronic bronchitis: a randomized double-blind prospective study in 180 patients. J Antimicrob Chemother. 1990;25(3):413–422. DOI: 10.1093/jac/25.3.413
  • 26. Takebe K., Imamura K., Masuda M., Murakami S., Tomiyama M., Tamura T., et al. A comparative study between cefodizime (CDZM) and cefotaxime (CTX) in respiratory tract infections. Kansenshogaku Zasshi. 1989;63(4):318– 351. DOI: 10.11150/kansenshogakuzasshi1970.63.318
  • 27. Zanussi C., Cocuzza G. Open, controlled, randomized study on the efficacy and safety of cefodizime single daily doze versus two daily doses and versus ceftriaxone single daily dose in patients with acute purulent bronchitis and acute purulent exacerbation of chronic bronchitis. J Chemother. 1995;7(6):535–542. DOI: 10.1179/joc.1995.7.6.535
  • 28. De Palma M., Rocchi D., Canepa G., Peri A., Cantone V. Single daily dose of cefodizime in patients with communityacquired pneumonia: an open-label, controlled, randomized study. The Italian Multicentre Community-Acquired Pneumonia Group. Clin Ther. 1995;17(3):413–424. DOI: 10.1016/0149–2918(95)80106–5
  • 29. Palombini B.C., André-Alves M.R., Dagrosa E.E. Cefodizime given in single or divided doses for the treatment of lower respiratory tract infection. Arzneimittelforschung. 1997;47(3):299–302. PMID: 9105549.
  • 30. Community-acquired pneumonia in adults. Clinical recommendations. Russian Respiratory Society. Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy. 2021. Available at: https://cr.minzdrav.gov.ru/schema/654_1. Accessed September 2023. Russian.
  • 31. Chronic obstructive pulmonary disease. Clinical recommendations. Russian Respiratory Society. 2021. Available at: https://spulmo.ru/upload/kr/HOBL_2021.pdf?ysclid=lkh23nanw8685838253. Accessed September 2023. Russian.
  • 32. Kozlov R.S., Golub A.V. Antimicrobial stewardship as a renascence of the ‘Golden Age’ of antibiotics. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2011;13(4):322–332. Russian.
  • 33. Golub A.V. Specifics of Russian pharmaceutical market in the XXI century: original drugs or generics? Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2009;11(4):335–340. Russian.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared